Company research · Merck & Co.
Merck & Co.: Full-year 2025 worldwide sales of $65.0 billion exceeded Fourth-quarter 2025 sales of $16.4 billion by 296.3%
The question
What is Merck & Co.: what does it do, how big is it and how is it doing, who owns and funds it, who runs it, and how do the company and the press describe it?
The 14 searches GAR ran
- site:merck.com investor relations annual report 2025
- site:merck.com newsroom press release
- Merck & Co. news 2026
- Merck & Co. criticism controversy concerns
- Merck & Co. company what it does products services
- Merck & Co. company overview founded headquarters industry
- Merck & Co. annual revenue employees 2025
- Merck & Co. revenue profit results 2026
- Merck & Co. funding round raised investors valuation
- Merck & Co. owner parent company stock listing
- Merck & Co. CEO founder leadership team
- Merck & Co. chief executive executives board
- Merck & Co. press release announcement 2026
- Merck & Co. mission strategy statement
GAR’s answer
Merck & Co. is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products, with full-year 2025 worldwide sales of $65.0 billion representing a 296.3% increase over its Fourth-quarter 2025 sales of $16.4 billion.
What we found
What it does
Merck & Co., Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. As of 2026, the company manufactures a variety of well-known pharmaceutical drugs, vaccines, and animal-health products. Its work spans the research, development, manufacture, and commercialization of medicines and vaccines for patients, healthcare professionals, health systems, and public-health customers. The company’s innovation model also relies on scientific partnerships, licensing, and co-development relationships that can extend its research pipeline and technical capabilities. [8] [9] [10]
The numbers
In the fourth quarter of 2025, Merck & Co. reported worldwide sales of $16.4 billion. For the full year 2025, the company recorded worldwide sales of $65.0 billion. This figure aligns with the revenue of 65011000000 USD reported in its annual SEC filing for the period ending 2025-12-31. In the prior year, ending 2024-12-31, the company reported revenue of 64168000000 USD in its SEC filing. Net income for the full year 2025 was 18254000000 USD according to the annual SEC filing, while net income for the full year 2024 was 17117000000 USD. A source dated 2026-10-16 lists net income (FY) as $18.25 B and net sales as $64.93 B. As of 2023, Merck’s net sales reached $22.2 billion. The company anticipates full-year 2026 worldwide sales to be between $65.5 billion and $67.0 billion. This outlook is supported by data indicating a full-year 2026 financial outlook of $65.5B. As of 2026, the company had 75 K employees. A source dated 2026-10-30 lists the market cap at $361.0B. [11] [12] [13] [14] [15] [18]
Funding and ownership
As of 2026, Merck & Co. reported a price to earnings ratio of 112.64 on a trailing twelve-month basis. The company indicated a dividend yield of 2.32% during this period. Data from 2026 shows that the shares float stood at 2.46 billion. For the fiscal year, the company recorded revenue of 64.93 billion USD. Net income for the same fiscal year was 18.25 billion USD. The workforce size was reported as 75,000 employees as of 2026. These financial metrics and ownership figures were sourced from TradingView data dated October 16, 2026, and reflect the company's status in that year. [14]
Who runs it
As of 2026, Rob Davis serves as the chairman of the board and chief executive officer of Merck & Co. The company’s executive leadership team includes Brian Foard, who holds the title of Executive vice president and president for Specialty, Pharma & Infectious Diseases. Gaurav Gupta serves as the Executive vice president and chief information and digital officer. Caroline Litchfield is the Executive vice president and chief financial officer. Jannie Oosthuizen acts as the Executive vice president and president for Oncology and MSD International. Additionally, Jennifer Zachary serves as the Executive vice president and general counsel. These individuals hold their respective positions according to information from www.merck.com dated 2026. [1] [16]
What the press says
Merck reported Q3 2026 revenue of 18.085 billion, with KEYTRUDA and KEYTRUDA QLEX sales reaching 8.601 billion and WINREVAIR sales at 694 million as of October 30, 2026. According to an April 13, 2026 report, Keytruda has generated $163 billion in sales since 2014, treating 3 million people. The company filed 1,212 Keytruda patent applications. In the United States, 60% of Keytruda sales occurred, with a list price of $6,015, compared to $850 in Indonesia. Merck paid $75 billion in dividends and $43 billion in share buybacks as of 2025. U.S. income taxes paid in 2025 were $1.6 billion, while the company provided $1.7 billion in free medicines in the U.S. in 2024. An estimate from 2026 projects the cost for lung cancer patients by 2040 at $5 billion. [6] [7]
What the company says
As of 2026, Merck states that KEYTRUDA (pembrolizumab) as monotherapy reduced the risk of disease progression or death by 43%. The company also reports that Sacituzumab Tirumotecan (Sac-TMT) reduced the risk of death by 32% and the risk of disease progression or death by 41%. In August 2026, Merck announced it would acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. On the same date, the company announced an acquisition of Pandion Therapeutics for an approximate total equity value of $1.85 billion. In October 2026, Merck and UPMC Enterprises made strategic investments totaling $5 million. This announcement noted that the estimated cost of hospital-acquired infections and inappropriate antimicrobial usage is $40 billion annually. It further stated that UPMC contributed $1.2 billion in benefits to its communities and paid $587 million in federal, state, and local taxes. [2] [3] [4] [5] [17]
| Metric (2026) | Value |
|---|---|
| KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death | 43% [2] |
| Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death | 32% [2] |
| Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Disease Progression or Death | 41% [2] |
Where the sources disagree
No disagreement found among the figures GAR compares: the same measure for the same period, and stakes in the same company. Other figures on this page are not checked against each other.
Analysis
Merck's revenue increased by 296.3% when comparing the fourth quarter of 2025 to the full year of 2025, indicating a substantial rise in sales over that specific period comparison. This suggests that the company's financial performance in the final quarter of 2025 was significantly higher than the total reported for the entire year, highlighting a strong surge in recent activity. [11]
Strengths and concerns
Strengths
- Change in revenue from Fourth-quarter 2025 to Full-year 2025: +296.3%. [11]
- Merck’s full-year 2025 revenue of $65.0 billion represents a significant scale of operations, supported by a 2026 outlook of $65.5 billion to $67.0 billion, indicating sustained commercial momentum for investors. [11]
- The company generated $18.25 billion in net income for fiscal year 2025, demonstrating strong profitability that underpins its ability to return capital to shareholders through dividends and buybacks. [14] [18]
- KEYTRUDA® (pembrolizumab) reduced the risk of disease progression or death by 43% in monotherapy trials, a clinical efficacy metric that supports the drug’s market position and long-term revenue potential. [2] [17]
- Sacituzumab Tirumotecan (Sac-TMT) reduced the risk of death by 32% and the risk of disease progression or death by 41%, highlighting the strength of Merck’s pipeline in delivering clinically significant outcomes. [2] [17]
- Merck’s market capitalization of $361.0 billion reflects its status as a major global healthcare entity, providing a stable investment base for shareholders. [15]
Concerns
- Merck’s revenue is heavily concentrated in a single product, Keytruda, which accounted for 60% of its sales in the U.S. and generated $8.601 billion in Q3 2026 alone, creating significant dependency risk if this drug faces competition or patent challenges. [6] [7]
- The company faces substantial patent litigation risks, evidenced by 1,212 Keytruda patent applications, which could threaten its dominant market position and future revenue streams. [7]
- Merck’s valuation is high relative to its earnings, with a Price to Earnings Ratio of 112.64, indicating that investors are pricing in significant future growth that may not materialize, increasing vulnerability to market corrections. [14]
- The company is pursuing large-scale acquisitions, including Acceleron Pharma for $11.5 billion and Pandion Therapeutics for $1.85 billion, which introduces integration risks and capital allocation pressures that could strain financial resources. [3] [4]
- Merck’s financial performance shows limited growth, with full-year 2025 worldwide sales of $65.0 billion and a 2026 outlook of only $65.5 billion to $67.0 billion, suggesting a plateau in revenue expansion despite high valuations. [11]
Sources
Researched and written by GAR, Octum’s cognitive engine, from the public sources listed above; every figure was checked automatically against the source it cites, and this version was reviewed by Octum before publication. First published 30 October 2026; updated 30 October 2026. Suggest a correction · Read as markdown